دورية أكاديمية
Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.
| العنوان: | Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients. |
|---|---|
| المؤلفون: | Berruti A; Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gonzole 10 10043 Orbassano (To), Italy., Bitossi R, Bottini A, Bonardi S, Donadio M, Nigro C, Bertetto O, Danese S, Bertone E, Sarobba MG, Farris A, Katsaros D, Castiglione F, Volpe T, Lattuada S, Mancarella S, Dogliotti L |
| المصدر: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2005 Jan; Vol. 41 (2), pp. 249-55. |
| نوع المنشور: | Clinical Trial; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print Cited Medium: Print ISSN: 0959-8049 (Print) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Elsevier Science Ltd Original Publication: Oxford ; New York : Pergamon Press, c1990- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Breast Neoplasms/*drug therapy , Vinblastine/*analogs & derivatives, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Confidence Intervals ; Dose-Response Relationship, Drug ; Epirubicin/administration & dosage ; Epirubicin/adverse effects ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Humans ; Infusions, Intravenous ; Middle Aged ; Vinblastine/administration & dosage ; Vinblastine/adverse effects ; Vinorelbine |
| مستخلص: | We investigated the activity and toxicity of a combination of vinorelbine 25 mg/m2 on days 1 and 15; epirubicin 25 mg/m2 on days 1, 8, 15; and 5-fluorouracil continuous infusion at 200 mg/m2 every day, administered as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients. Fifty-three patients entered the study. Cycles were repeated every 28 days. Objective response was 60% by World Health Organisation (WHO) criteria and 63% by Response Evaluation Criteria in Solid Tumours (RECIST). The median time to progression was 12.7 months (17.6 months in responders) and the median survival duration was 32.9 months. The dose-limiting toxicity was leucopenia (grade 3/4 in 36% of patients). Grade 3/4 non-haematological toxicities included mucositis in 11% of patients, skin and cardiac toxicity in 4% and 2%, respectively. The combination of vinorelbine, epirubicin and 5-fluorouracil continuous infusion was found to be an active and manageable first-line regimen for metastatic breast cancer patients. |
| المشرفين على المادة: | 3Z8479ZZ5X (Epirubicin) 5V9KLZ54CY (Vinblastine) Q6C979R91Y (Vinorelbine) U3P01618RT (Fluorouracil) |
| تواريخ الأحداث: | Date Created: 20050122 Date Completed: 20050322 Latest Revision: 20181201 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.ejca.2004.07.003 |
| PMID: | 15661550 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 0959-8049 |
|---|---|
| DOI: | 10.1016/j.ejca.2004.07.003 |